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In the current issue of the Archives of Medical Science two studies from
the same group, an academic community cardiology practice [1, 2], address
the issue of the impact of the implementation of secondary cardiovascu-
lar disease (CVD) prevention guidelines on the long-term clinical outcome
in patients with established coronary artery disease (CAD). 
In the 1st study [1] the differences in medication usage and in CVD event
rates are reported. From the early era (before 2002) to the later era (2005-
2008), there was an increase in the use of β-blockers (from 66% to 83%, 
p < 0.0001), angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin
receptor blockers (ARBs) (from 34% to 80%, p < 0.0001), and statins (from
40% to 90%, p < 0.0001). This resulted in a substantial CAD rate reduction
(9.2% vs. 29.1% in the later vs. early time period; p < 0.0001) [1]. In the sec-
ond study that included a different population [2], CAD patients were not
initially treated with statins during the first year of being seen in an outpa-
tient cardiology practice but subsequently treated with statins (100%) for
a mean period of 66 months. Myocardial infarction (MI) occurred in 10% of
patients before statins, and in 4% after statins (p < 0.01), percutaneous coro-
nary intervention (PCI) had been performed in 22% of patients before statins
and in 13% after statins (p < 0.01), and coronary artery bypass graft (CABG)
surgery had been performed in 18% of patients before statins and in 7%
after statins (p < 0.001) [2]. These two studies point out that the imple-
mentation of secondary CVD prevention guidelines in a “real world” setting
have a considerable positive impact on subsequent CVD morbidity and mor-
tality [1, 2]. 
Several studies have demonstrated improved clinical outcomes when
key quality-of-care indicators are implemented in the management of
patients with acute coronary syndromes (ACS) or stable CAD [3]. Howev-
er, secondary prevention guidelines can be poorly implemented [4, 5]. Par-
ticularly, in regard to statins, which have to be taken indefinitely, there is
a concern that poor compliance may compromise their benefit [4-7].
Patients with dyslipidaemia do not experience symptoms and they need
motivation to adhere to their medication. Clinical trials are performed at
a controlled environment and data reported by them may vary from “real
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life data” [6, 7]. For example a US study that report-
ed the 2-year adherence of a non-selected 
MEDICAID cohort showed that only < 40% of
patients were on a statin > 80% of the time [8]. The
large US registry CRUSADE (Can Rapid Risk Strati-
fication of Unstable Angina Patients Suppress
Adverse Outcomes With Early Implementation of
the ACC/AHA Guidelines), the EUROASPIRE I, II, III
real world data on effective treatment of stable
CAD, and the international Global Registry of Acute
Coronary Events (GRACE) study demonstrated
a world-wide underuse of proven medical thera-
pies, including statins, among patients with either
ACS or stable CAD [4, 9, 10]. Therefore, the gap
between guidelines and routine clinical practice
seems to have persisted during the decade 2000
to 2010 [11] and is a universal phenomenon [12-18].
Bridging the care gap in secondary CVD prevention
remains a significant challenge. The lost benefit due
to undertreatment contributes to the CVD burden.
In addition to diet, exercise and lifestyle interven-
tions new strategies are urgently needed to opti-
mize vascular disease management in secondary
prevention. 
There have been prospective attempts to
improve this situation, but mainly focused on the
time after the acute event. A simplified treatment
algorithm that initiated secondary CVD protection
measures before hospital discharge in patients with
an ACS was tested in the Cardiac Hospitalization
Atherosclerosis Management Program (CHAMP)
during the 90’s [19]. CHAMP was associated with
a significant increase in use of medications that
had been demonstrated to reduce mortality after
ACS. Comparison of the pre- and post-CHAMP
patient groups showed that aspirin use at discharge
improved from 68% to 92% (p < 0.01), β-blocker use
from 12% to 62% (p < 0.01), ACE-I use increased
from 6% to 58% (p < 0.01), and statin use increased
from 6% to 86% (p < 0.01). This increased use of
treatment persisted during subsequent follow-up.
During this programme a high percentage of
patients achieved secondary CVD prevention tar-
gets including low density lipoprotein cholesterol
(LDL-C) goal (< 100 mg/dl) (58% in post-CHAMP vs.
6% pre-CHAMP, p < 0.001). This translated in an
improvement in clinical outcome; the incidence of
non-fatal MI and cardiac death was cut by half in
the 1-year follow-up [19]. Another major attempt to
improve implementation of guidelines was the real-
time American College of Cardiology Guidelines
Applied in Practice (GAP) programme. The GAP tools
also resulted in higher discharge rates of second-
ary prevention medication (aspirin, β-blockers, ACE I
and statins) [20]. The GAP tools were associated
with fewer rehospitalizations for CAD, MI, and com-
bined death/cerebrovascular event/MI in the first
1-year of follow-up. The CVD mortality substantial-
ly declined during the post-GAP period [20]. The
Swedish Quality Control Programme [21] is the first
attempt to assess implementation of CVD treat-
ment guidelines on a national level. After 1 year
a large proportion of patients were still on preven-
tive drugs: aspirin (96%), β-blockers (78%) and lipid-
lowering drugs (83%), but no actual clinical results
have been reported yet [21]. 
There have been only a few attempts to improve
adherence in secondary CVD prevention drugs away
from the acute event, taking into account “real word
data”. This is why the 2 studies [1, 2] published in
this issue are valuable, despite their retrospective
design.
From 1998 to 2002 the prospective, randomised,
and controlled GReek Atorvastatin on Coronary-
heart-disease Evaluation (GRACE) study was car-
ried out [22]. This was the first target based study,
aiming to assess the clinical benefit from attaining
the LDL-C goal (< 100 mg/dl) in 1,600 consecutive
patients with established CAD. Patients were ran-
domised either to “structured care” (n = 800) with
dose titrating of atorvastatin (from 10 to 80 mg/
day) in order to achieve the LDL-C target or to 
“usual” medical care (n = 800). All patients were
followed for a mean period of 3 years [22]. There
was an orchestrated effort to keep the “structured
care” patients on atorvastatin and the LDL-C < 100
mg/dl (mean dosage of atorvastatin: 24 mg/day).
This was achieved in 95% of patients, at a level
much higher than “usual care” (12 on statins, 3%
on LDL-C target). Other secondary CVD prevention
therapies had no difference between the 2 treat-
ment groups [22]. During the study 196 (24.5%) CAD
patients on “usual” care had a CAD recurrent event
or died vs. 96 (12%) CAD patients on “structured
care”; risk ratio (RR) 0.49, confidence interval (CI)
0.27-0.73, p < 0.0001. In detail, structured care
reduced, in comparison to “usual care”, total mor-
tality (RR 0.57, 95% CI 0.39-0.78, p = 0.002), coro-
nary mortality (RR 0.53, 95% CI 0.29-0.74, p= 0.0016),
coronary morbidity (RR 0.46, 95 % CI 0.25-
0.71, p < 0.0001), and stroke (RR 0.53, 95% CI 0.30-
0.82, p = 0.0018) [22]. All subgroups of patients
(women, those with diabetes mellitus, arterial
hyper  tension, age 60 to 75 years, congestive heart
failure or prior revascularization) benefited from
treatment with atorvastatin. Withdrawal of patients
because of side effects from the atorvastatin group
was low (0.75%), similar to that of the “usual” care
group (0.4%) [22]. Similar were the results of the
Aggressive Lipid-Lowering Initiation Abates New
Cardiac Events (ALLIANCE) study, published 2 years
later [23]. In ALLIANCE an aggressive, focused statin
therapy management strategy outperformed “usu-
al care” in health maintenance organization and
Veterans Administration clinic patients with CAD.
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mary outcome (time to first CVD event: HR, 0.83;
95% CI 0.71 to 0.97, p = 0.02). This reduction in
morbidity was largely due to fewer non-fatal
myocardial infarctions (47% reduction, p = 0.0002)
[23]. This benefit was less than that reported by
GREACE, but this study came 2 years later (sec-
ondary prevention improves with time) and was
performed in US, where “usual care” was better
than that in Greece. 
Very recent data on primary CVD prevention are
very encouraging. These show that first MI (within
primary CVD prevention) and subsequent short
term (30 day) mortality halved over the last 10-25
years in at least 3 European countries [24-26].
From 2002 to 2010 in England, the age stan-
dardised total mortality rate fell by about half,
whereas the age standardised CVD event and case
fatality rates both declined by about one third. This
was reported from the analysis of the data that
included 840,175 people of all ages who were admit-
ted to hospital for acute MI or died suddenly from
acute MI. Half of the decline in deaths from acute
MI during the 2000s in England can be attributed
to a decline in event rate and half to improved sur-
vival at 30 days. Both prevention of first acute MI
by addressing CVD risk factors and medical treat-
ment during the acute phase hospitalization have
contributed to the decline in deaths from acute MI
over the past decade [24].
In addition, over half of the recent fall in mor-
tality from CAD in Poland can be attributed to
reductions in major risk factors and about one third
to evidence based medical treatments. The CAD
deaths in Poland plummeted after the socioeco-
nomic reform in 1989. From 1991 to 2005, the death
rate from CAD in Poland halved in people aged 25-
74 years [25]. About 54% of the fall was attributed
to changes in risk factors, mainly reductions in total
cholesterol (39%) and an increase in physical activ-
ity (10%). These benefits were partially offset by
increases in body mass index (–4%) and diabetes
(–2%). Blood pressure fell in women, explaining
about 29% of their decrease in mortality, but rose
in men generating a negative influence (–8%).
About 15% of the observed decrease in mortality
was attributable to reduced smoking in men but
this effect was negligible in women [25].
Finally, a study that included ~ ~250,000 Danish
people and followed them up for 25 years showed
that the rate of first MI and subsequent short-term
mortality declined by nearly half between 1984 and
2008. The reduction in mortality occurred for all
patients, independent of sex and comorbidity. How-
ever, comorbidity burden was a strong prognostic
factor for short and long-term mortality, while gen-
der was not. It was estimated that half of the
decline in mortality since 1980 is attributable to pri-
mary prevention of MI (reduction in the prevalence
of major CVD risk factors such as smoking, seden-
tary lifestyle, and uncontrolled high blood pres  -
sure) [26]. The other half is attributable to the intro-
duction of thrombolysis, CABG, PCI, and antiplatelet
regimens, β-blockers, ACE-I, and statins. It is rele-
vant that the incidence of MI has continued to
decline despite increased prevalence of obesity and
diabetes [26]. 
Thus, the effort to address any excess CVD risk
(though lower now in absolute terms than in the
past) related to comorbidies has an outstanding
place in primary CVD prevention and can further
reduce CVD events and mortality. This was the rea-
son that we carried out 4 “best practice” studies
(aiming in attending international guidelines for
CVD prevention) in order to deal with major comor-
bidities in a primary care setting, mainly in primary
prevention patients [27-30]. The results of these
studies suggest that the estimated risk for a fatal
or non-fatal CVD event was nearly halved at 
6 months of treatment, by multifactorial interven-
tion in patients with at least one major CVD risk
factor (arterial hypertension, dyslipidaemia, dia-
betes, and metabolic syndrome) [27-30]. Another
best practice study showed that this was the case
for long-term morbidity and mortality also in
patients with metabolic syndrome [31]. Other
comorbidies, increasing CVD risk, such as chronic
kidney disease [32-34] and non-alcoholic fatty liv-
er disease [35-37] should be diagnosed and treat-
ed accordingly. Also, in patients with metabolic syn-
drome, multifactorial intervention resulted in
elimination of new cases of diabetes [38, 39], which
is considered to be as harmful as pre-existing dia-
betes [40]. In any case statin treatment plays
a great role in primary CVD prevention. A recent
meta-analysis [41] showed that statins were found
to be efficacious in preventing death and CVD mor-
bidity in people at low CVD risk (without CAD or dia-
betes), within primary prevention. Reductions in RR
were similar to those seen in patients with a his-
tory of CAD [41].
The data suggest that there is plenty of room in
real world settings for a better implementation of
guidelines in secondary CVD prevention (bridging
the gap between guidelines and everyday clinical
practice) with substantial clinical gains. Efforts like
the ones in the 2 Studies in this issue of the jour-
nal [1, 2] are welcomed. On the other hand, effec-
tive risk factor control in primary CVD prevention
leads to fewer MIs, while effective treatment meas-
ures during the acute phase of MI results in halv-
ing short- and long-term CVD mortality. However,
there is still room for further improvement by
addressing major comorbidities (especially the
forthcoming epidemic of diabetes), which shape
acute- and long-term mortality in men and women
[42]. Interventions both in primary and secondary
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CVD prevention will finally lead to substantial reduc-
tion of the human cost of this disease.
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